Vocimagene amiretrorepvec-flucytosine gene therapy - Tocagen

Drug Profile

Vocimagene amiretrorepvec-flucytosine gene therapy - Tocagen

Alternative Names: Cytosine deaminase gene therapy-flucytosine; Flucytosine prodrug activating therapy - Tocagen; Toca 511 & Toca FC; Toca 511 + 5-FC; Toca-511 + Toca-FC; Vocimagene amiretrorepvec + 5-fluorocytosine; Vocimagene amiretrorepvec + flucytosine

Latest Information Update: 27 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tocagen
  • Class Antineoplastics; Cytosine deaminase-flucytosine-gene-therapies; Pyrimidinones; Small molecules
  • Mechanism of Action DNA synthesis inhibitors; Gene transference; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Anaplastic astrocytoma; Glioblastoma
  • Phase I Glioma; Solid tumours
  • Preclinical Breast cancer

Most Recent Events

  • 24 Jul 2017 Vocimagene amiretrorepvec-flucytosine gene therapy - Tocagen receives Priority Medicine (PRIME) status for Glioma (Recurrent) in European Union
  • 23 Feb 2017 Vocimagene amiretrorepvec-flucytosine gene therapy - Tocagen receives Breakthrough Therapy status for Glioma (Recurrent) in USA
  • 23 Feb 2017 Tocagen completes enrolment in the phase II portion of the phase II/III Toca 5 trial for Anaplastic astrocytoma (Recurrent) and Glioblastoma (Recurrent) in Canada, israel, South Korea and USA (NCT02414165)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top